Tadao Akizawa1, Iain C Macdougall2, Jeffrey S Berns3, Hiroyasu Yamamoto4, Megumi Taguchi5, Kazuma Iekushi5, Thomas Bernhardt6. 1. Division of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan, akizawa@med.showa-u.ac.jp. 2. Department of Renal Medicine, King's College Hospital, London, United Kingdom. 3. Perelman School of Medicine at the University of Pennsylvania, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA. 4. Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan. 5. Bayer Yakuhin Ltd., Osaka, Japan. 6. Bayer Pharma AG, Berlin, Germany.
Abstract
BACKGROUND/AIMS: The current treatment for anemia associated with chronic kidney disease (CKD) includes the administration of erythropoiesis stimulating agents (ESAs) combined with iron supplementation. Molidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, has potential to treat anemia associated with CKD through increased erythropoietin production and improved iron availability. Here, we report the effect of molidustat on iron metabolism. METHOD: Parameters of iron metabolism were monitored in three 16-week, randomized, controlled, phase 2 studies assessing the safety and efficacy of molidustat in the treatment of anemia associated with CKD in different populations: treatment-naïve and previously ESA-treated patients not on dialysis, and previously ESA-treated patients on hemodialysis. Iron supplementation was left at the discretion of the investigator. RESULTS: In treatment-naïve patients not on dialysis, transferrin saturation (TSAT), hepcidin, ferritin, and iron concentrations decreased with molidustat, whereas total iron binding capacity (TIBC) increased. Similar results were observed in previously ESA-treated patients not on dialysis, although changes in those parameters were larger in treatment-naïve than in previously ESA-treated patients. In previously ESA-treated patients receiving hemodialysis, hepcidin concentration and TIBC remained stable with molidustat, whereas TSAT and ferritin and iron concentrations increased. Generally, similar trends were observed in secondary analyses of subgroups of patients not receiving iron supplementation. CONCLUSIONS: Molidustat is a potential alternative to standard treatment of anemia associated with CKD, with a different mechanism of action. In patients not receiving dialysis, molidustat increases iron availability. In patients receiving hemodialysis, further investigation is required to understand fully the mechanisms underlying iron mobilization associated with molidustat.
RCT Entities:
BACKGROUND/AIMS: The current treatment for anemia associated with chronic kidney disease (CKD) includes the administration of erythropoiesis stimulating agents (ESAs) combined with iron supplementation. Molidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, has potential to treat anemia associated with CKD through increased erythropoietin production and improved iron availability. Here, we report the effect of molidustat on iron metabolism. METHOD: Parameters of iron metabolism were monitored in three 16-week, randomized, controlled, phase 2 studies assessing the safety and efficacy of molidustat in the treatment of anemia associated with CKD in different populations: treatment-naïve and previously ESA-treated patients not on dialysis, and previously ESA-treated patients on hemodialysis. Iron supplementation was left at the discretion of the investigator. RESULTS: In treatment-naïve patients not on dialysis, transferrin saturation (TSAT), hepcidin, ferritin, and iron concentrations decreased with molidustat, whereas total iron binding capacity (TIBC) increased. Similar results were observed in previously ESA-treated patients not on dialysis, although changes in those parameters were larger in treatment-naïve than in previously ESA-treated patients. In previously ESA-treated patients receiving hemodialysis, hepcidin concentration and TIBC remained stable with molidustat, whereas TSAT and ferritin and iron concentrations increased. Generally, similar trends were observed in secondary analyses of subgroups of patients not receiving iron supplementation. CONCLUSIONS:Molidustat is a potential alternative to standard treatment of anemia associated with CKD, with a different mechanism of action. In patients not receiving dialysis, molidustat increases iron availability. In patients receiving hemodialysis, further investigation is required to understand fully the mechanisms underlying iron mobilization associated with molidustat.
Authors: Matthew Taylor; Aijuan Qu; Erik R Anderson; Tsutomu Matsubara; Angelical Martin; Frank J Gonzalez; Yatrik M Shah Journal: Gastroenterology Date: 2011-03-17 Impact factor: 22.682
Authors: Angelo Karaboyas; Jarcy Zee; Hal Morgenstern; Jacqueline G Nolen; Raymond Hakim; Kamyar Kalantar-Zadeh; Philip Zager; Ronald L Pisoni; Friedrich K Port; Bruce M Robinson Journal: Clin J Am Soc Nephrol Date: 2015-08-18 Impact factor: 8.237
Authors: Damien R Ashby; Daniel P Gale; Mark Busbridge; Kevin G Murphy; Neill D Duncan; Tom D Cairns; David H Taube; Stephen R Bloom; Frederick W K Tam; Richard S Chapman; Patrick H Maxwell; Peter Choi Journal: Kidney Int Date: 2009-02-11 Impact factor: 10.612
Authors: Pablo E Pergola; Bruce S Spinowitz; Charlotte S Hartman; Bradley J Maroni; Volker H Haase Journal: Kidney Int Date: 2016-09-17 Impact factor: 10.612
Authors: Megan L Noonan; Pu Ni; Rafiou Agoro; Spencer A Sacks; Elizabeth A Swallow; Jonathan A Wheeler; Erica L Clinkenbeard; Maegan L Capitano; Matthew Prideaux; Gerald J Atkins; William R Thompson; Matthew R Allen; Hal E Broxmeyer; Kenneth E White Journal: J Bone Miner Res Date: 2021-03-10 Impact factor: 6.741
Authors: Patrizia Natale; Suetonia C Palmer; Allison Jaure; Elisabeth M Hodson; Marinella Ruospo; Tess E Cooper; Deirdre Hahn; Valeria M Saglimbene; Jonathan C Craig; Giovanni Fm Strippoli Journal: Cochrane Database Syst Rev Date: 2022-08-25